Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non- Small Cell Lung Cancer: Implications for Precision Medicine

The heterogeneous relationship between protein expression, ampli fication, and mutations in human epidermal growth factor receptor 2 (HER2) in non -small cell lung cancer (NSCLC) and the optimal methods for detecting these alterations remain unclear. We aimed to elucidate the clinicopathological and molecular characteristics of HER2 -altered NSCLC and investigate practical approaches for identifying patients who might bene fit from HER2 -targeted therapies. Using next -generation sequencing data from 1680 individuals, we searched for patients with HER2 -altered NSCLCs, including ampli fications and mutations. Clinicopathological data and tissue slides were reviewed. Immunohistochemistry (IHC) and silver in situ hybridization were performed according to the American Society of Clinical Oncology/College of American Pathologists guidelines. Our analysis identi fied 89 (5.3%) patients with HER2 -altered NSCLCs, comprising 30 (1.8%) with ampli fication and 59 (3.6%) mutations, and they were compared with 165 control patients. Of the 59 HER2-mutated cases, 52 harbored tyrosine kinase domain (TKD) mutations, primarily HER2 exon 20 insertions. HER2 TKD alterations were associated with younger age, female sex, nonsmoking status, adenocarcinoma with a micropapillary pattern, lung -to -lung metastasis, and poor overall survival. The 33 patients with TKD mutations and 3 with non-TKD point mutations showed incomplete or complete membranous HER2 immunoreactivity (1+ and 2+, 61.07%). Six patients exhibiting ampli fications had an IHC score of <= 2+ despite their high copy numbers and concomitantly displayed other actionable EGFR , KRAS , SMARCA4 , and other HER2 mutations. These HER2- altered NSCLCs with molecular coalterations showed heterogeneous patterns through HER2 IHC and silver in situ hybridization. Therefore, next -generation sequencing should be used to identify HER2 mutations in patients with NSCLC who present with concomitant alterations. In addition, the above clinicopathological characteristics and HER2 IHC results can be valuable determinants for identifying patients with HER2 -altered NSCLC. These insights hold promise for the development of more effective diagnostic and therapeutic strategies for this complex subset of NSCLC patients. (c) 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.